

Ontario Public Drug Programs

Drug Submission Status

Generic Name: plerixafor

Brand Name: Mozobil

Strength: 24 mg/1.2 mL (20 mg/mL) subcutaneous solution

Manufacturer: Genzyme Canada Inc.

Indication: In combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma

Rapid Review: Not requested

Submission Type:	Date Submission Received:	Date Submission Deemed Complete:	Review Status:	Funding Decision:
First Review (Initial Submission)	11/06/2012	04/07/2012	EO decision rendered	Funding considered through Cancer Care Ontario's New Drug Funding Program

Rapid Review:

Details of the Rapid Review process can be found at:

www.health.gov.on.ca/en/pro/programs/drugs/drug_submissions/rapid_review_process.aspx

Review Status:

- Screening – Ministry is screening the manufacturer's submission to ensure all regulatory and policy requirements have been met in order to proceed with the drug review.
- Submission incomplete – Manufacturer did not meet the necessary requirements to allow review to proceed.

- Submission complete & under review – Manufacturer met all requirements to proceed with the drug review, and evaluation of the drug submission is underway.
- Committee to Evaluate Drugs (CED) review completed, manufacturer requesting reconsideration – A recommendation was made by the CED, however the manufacturer has submitted or will be submitting additional information.
- Committee to Evaluate Drugs (CED) review completed – A recommendation was made by the CED.
- Executive Officer (EO) decision rendered.

Funding Status:

The Committee to Evaluate Drugs (CED) recommendation and the Executive Officer (EO) decision, if available, can be found at:

www.health.gov.on.ca/en/pro/programs/drugs/ced_rec_table.aspx

Updated: February 20, 2014